New mesothelioma drug doesn’t extend patients’ lives, clinical trial finds

An AstraZeneca drug failed to prolong the lives of patients with the rare but lethal cancer mesothelioma in a clinical trial, the company said today. Tremelimumab did not extend the lives of severely-ill patients when given on its own but the company said it is hopeful the drug will have a role to play in combination treatments.

“We are disappointed that tremelimumab monotherapy did not demonstrate a survival benefit in this patient population with no approved medicines beyond first-line treatment. However, we remain confident in tremelimumab’s clinical activity in combination, as shown in our recently published Study 006 trial of tremelimumab and durvalumab in non-small cell lung cancer,” Robert Iannone, Senior Vice President, Head of Immuno-Oncology, Global Medicines Development at AstraZeneca, said.

Tremelimumab is also being tested in combination with another of AstraZeneca’s immune-boosting drugs, durvalumab, in multiple tumor cases, including non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck, bladder, pancreatic, gastric and liver cancers.

Mesothelioma is a deadly form of cancer that affects the lining of the lungs or abdomen. It is most often seen in patients who have been exposed to asbestos.



About the Author

Truman Lewis
A former reporter and bureau chief, Truman Lewis has covered presidential campaigns, state politics and stories ranging from organized crime to environmental and consumer protection.